Eli Lilly (LLY) Stock Surges 4% Following Breakthrough Sleep Apnea Trial Results

Eli Lilly (LLY) stock jumped 4% after Phase 3 data revealed retatrutide cut sleep apnea by 60% and knee pain by 73%, outpacing rival Novo Nordisk.

The post Eli Lilly (LLY) Stock Surges 4% Following Breakthrough Sleep Apnea Trial Results appeared first on Blockonomi.